Seer's Proteograph Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a leading life science innovator shaping the future of proteomics, is set to present significant advancements at the 23rd Human Proteome Organization (HUPO) World Congress in Dresden, Germany, from October 20-24, 2024. As a HUPO sponsor, Seer will showcase novel findings that are driving the adoption and expansion of proteomic science, demonstrating the unique power of its Proteograph Product Suite to accelerate proteomic research at scale.
Seer's foundational technologies redefine how the research community approaches proteomic analysis, making it possible to tackle complex biological questions with an unprecedented level of depth, scalability, and efficiency. By automating key processes and compressing the dynamic range of the proteome, Seer's solutions empower researchers to generate meaningful insights into human health and disease, which are essential for personalized medicine, biomarker discovery, and population health studies.
"The advanced research being presented this week is the latest in a rapidly growing body of evidence demonstrating how the Proteograph Product Suite is empowering researchers to generate deep, unbiased proteomic data at a speed and scale previously unattainable," said Omid Farokhzad, CEO and Chair at Seer. "We're at the leading edge of innovation to provide researchers with the tools they need to understand complex biology at a molecular level, driving the field toward transformative breakthroughs in precision medicine."
Highlights from Seer at HUPO 2024:
Alzheimer's Disease: Exploring Genetic Influence with Unbiased Proteogenomics to Uncover Unexpected Disease Pathways
Title: Understanding the Impact of Genetic Variants on Alzheimer's Disease with Mass Spectrometry Proteogenomics
Presenter: Harendra Guturu
Date & Time: October 23, 13:00 (Poster Session P-III-1031)
Leveraging Seer's Proteograph XT, this study analyzes almost 1,800 plasma samples from 1,005 participants of the Massachusetts General Hospital Alzheimer's Disease Cohort, exploring the connection between genetic variants and proteomic alterations associated with Alzheimer's Disease. By combining mass spectrometry-based proteomics and Mendelian randomization, this analysis uncovered 138 differentially abundant protein groups between healthy and Alzheimer's-affected individuals, pinpointing possible causal pathways linked to disease progression. This approach demonstrates how Seer's platform facilitates comprehensive coverage and effectively correlates genetic and proteomic data, providing an unbiased exploration of complex diseases. This research advances the understanding of systemic factors in Alzheimer's, potentially revealing new biomarkers and therapeutic targets that targeted methods might overlook.
Population Health Studies: Achieving Population-Scale Plasma Proteomics with Novel Speed and Depth to Drive New Discoveries
Title: Empowering Robust Population-Scale MS Plasma Proteomics Studies with Nanoparticle Enrichment
Presenter: Lee Cantrell
Date & Time: October 21, 13:15 (Poster Session P-I-0212)
Seer's Proteograph XT was applied in a population study involving 1,600 plasma samples, combining nanoparticle enrichment, plate-based automated preparation, and MS measurements to achieve significant depth at scale. With over 8,100 protein groups identified and processing throughput reaching 40 samples per day, the cloud-based DIA-NN integration accelerated data analysis up to twenty times faster compared to standard computational frameworks. By compressing the dynamic range of plasma proteins and enhancing peptide diversity, this workflow circumvents typical bottlenecks like manual fractionation and depletion, delivering higher coverage with minimized handling time. This capability is particularly valuable for discovery proteomics researchers looking to generate biological insights efficiently, offering significant gains in both depth and throughput.
Whole Blood Microsampling: Extending Accessibility of Proteomics through Novel DBS Analysis for Comprehensive Biomarker Studies
Title: Advancement in Nanoparticle-Based Proteomic Analysis of Whole Blood Obtained from Various Dried Blood Spot Collection Devices
Presenter: Maik Pruess
Date & Time: October 21, 13:15 (Poster Session P-I-0165)
This study focused on proteomic analysis using dried blood spot (DBS) samples, a method enabling less invasive sampling with broader clinical applications. The integration of Seer's nanoparticle enrichment improved the number of proteins detected—from approximately 1,000 to up to 3,000 when compared to conventional direct processing methods. The approach demonstrated low variability across subjects (CV <10%) and illustrated the applicability of Proteograph XT for large-scale studies involving minimal sample volumes. By combining DBS with nanoparticle enrichment, researchers are enabled to conduct in-depth proteomic analysis from minimal samples, which is key for early biomarker discovery. This approach facilitates a more inclusive and accessible model for proteomic research compared to traditional methods, supporting innovation at both individual and population scales.
Xenotransplantation: Capturing Immune Dynamics with Ultra-Deep Longitudinal Profiling for Novel Insights in Transplant Research
Title: Ultra-Deep Longitudinal Profiling of Plasma and Serum Proteome Provides Critical Insights into the Interaction of Human Organism and Pig Xenotransplants
Presenter: Alexey Stukalov
Date & Time: October 22, 11:05 (Oral Presentation OP-43)
In a pioneering study of xenotransplantation performed with collaborators at multiple high-profile research institutions, Seer's Proteograph XT was used to perform ultra-deep profiling of plasma and serum proteomes from recipients of genetically modified pig organs. The integration of Proteograph XT with advanced LC-MS workflows (Thermo Scientific Orbitrap Astral MS) enabled comprehensive identification of both human and pig proteins over a period of 61 days, including over 100,000 peptides. This provided a detailed view of immune system responses, complement system dynamics, and physiological adaptation in real-time. For researchers focused on human health and organ transplantation, this study highlights Seer's platform's ability to support deep longitudinal sampling and comparative proteomics, facilitating the identification of biomarkers and immune responses important to advancing xenotransplantation and immunological research.
Highlights from External Collaborators and Customers Utilizing Seer's Proteograph Product Suite
Respected organizations from around the world are presenting research at HUPO 2024 that utilized Seer's Proteograph platform, demonstrating its versatility and value across different proteomic studies. These collaborations highlight Seer's role as a key enabler in bridging discovery proteomics and clinical applications. Collaborators leverage Seer's platform for a range of studies from drug discovery to preclinical models, reinforcing the Proteograph Product Suite's effectiveness in generating deep and unbiased insights across diverse contexts. These posters reflect how Seer's technology enhances sensitivity, scalability, and depth of proteomic workflows.
External Presentations:
- Stanford University
- Keynote Lecture: Disrupting healthcare using deep data and remote monitoring
- Presenter: Michael Snyder
- Section/Session: New technologies for large scale proteomics
- Date & Time: October 23, 10:15 (Conference Room 1-2)
- Evotec
- Title: Nanoparticle-based proteomics analysis of human biofluid samples from different patient cohorts
- Authors: Carleen Kluger, Giada Marino
- Date & Time: October 21, 13:15 (Poster Session P-I-0363)
- Thermo Fisher Scientific (Poster 1)
- Title: Unveiling Hidden Depths: A High-Throughput Plasma Proteomics Workflow on Orbitrap Astral Mass Spectrometer for Enhanced Biomarker Discovery
- Author: Amirmansoor Hakimi
- Date & Time: October 21, 13:15 (Poster Session P-I-0124)
- Thermo Fisher Scientific (Poster 2)
- Title: An In-Depth and High Throughput Plasma Proteomics Workflow Powered by Orbitrap Exploris 480 Mass Spectrometer Using Multi Nanoparticle-Based Workflow
- Author: Julian Saba
- Date & Time: October 22, 13:00 (Poster Session P-II-0661)
- Inserm (French National Institute of Health and Medical Research)
- Title: In-Depth Analysis of the Plasma Proteome: Are We Enriching Extracellular Vesicles, Platelets, or Soluble Proteins?
- Author: Ida Chiara Guerrera
- Date & Time: October 21, 13:15 (Poster Session P-I-0331)
- Seoul National University
- Title: Discovery of Plasma Biomarkers in Dogs Afflicted with Mammary Gland Tumors through Proteograph Analysis
- Author: Jeong-Woon Lee
- Date & Time: October 22, 13:00 (Poster Session P-II-0604)
- Ted Rogers Centre for Heart Research
- Title: Comprehensive Plasma Proteomics in Heart Failure Patients: Findings and Future Directions
- Author: Uros Kuzmanov
- Date & Time: October 23, 13:00 (Poster Session P-III-1048)
- Oregon Health and Science University (OHSU)
- Title: Study of Fundamental Biological Determinants of the Plasma Proteome Using Proteograph Rise and Murine Models
- Authors: Mark Flory and Matthew Chang
- Date & Time: October 23, 13:00 (Poster Session P-III-0938)
Seer's contributions at HUPO 2024 are reflected not only in its research but also in the adoption of its Proteograph Product Suite by leading academic and industry groups. The broad array of external studies showcases the applicability and value of Seer's technologies in advancing proteomics research, enriching understanding, and pushing the frontiers of biological analysis.
About Seer:
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit .
For more information, please visit Booth #20 at HUPO 2024 or contact us at pr@seer.bio.
Media Contact: Patrick Schmidt pr@seer.bio
Investor Contact: Carrie Mendivil investor@seer.bio
Seer的Proteograph產品套件揭示了有關 Alzheimer 病毒通路的新見解,推動了規模化血漿分析,並捕獲了異種移植中的免疫動態-並且在合作伙伴的額外突破性研究的推動下,促進了規模化蛋白質組學發現
加州雷德伍德城,2024年10月21日(GLOBE NEWSWIRE)-- Seer公司 (納斯達克: SEER)是領先的生命科學創新者,塑造着蛋白質組學的未來,將在2024年10月20日至24日於德國德累斯頓舉辦的第23屆人類蛋白組織(HUPO)世界大會上展示重大進展。作爲HUPO的贊助商,Seer將展示推動蛋白質組學科學採用和擴展的新發現,展示其Proteograph產品套件的獨特力量,以加速大規模蛋白質組研究。
Seer的基礎技術重新定義了研究界如何進行蛋白質組分析,使得能夠以前所未有的深度、可伸縮性和效率解決複雜的生物學問題。通過自動化關鍵流程和壓縮蛋白質組的動態範圍,Seer的解決方案賦予研究人員生成有意義的人類健康和疾病見解的能力,這對於個性化醫學、生物標誌物發現和人群健康研究至關重要。
"本週展示的先進研究是越來越多的證據的最新產物,證明了Proteograph產品套件如何讓研究人員以前所未有的速度和規模生成深入、無偏見的蛋白質組數據," Seer首席執行官兼董事Omid Farokhzad說,"我們處於創新的前沿,爲研究人員提供了他們需要理解分子水平復雜生物學的工具,推動該領域朝着在精準醫學方面實現變革性突破的方向發展。"
賽默飛世爾在HUPO 2024的亮點:
阿爾茨海默病:通過無偏見的蛋白質組學探索遺傳影響,揭示意想不到的疾病途徑
標題:利用質譜蛋白組學了解遺傳變異對阿爾茨海默病的影響
演講者:Harendra Guturu
日期和時間:10月23日,13:00(海報展示P-III-1031)
利用Seer的Proteograph Xt,這項研究分析了來自馬薩諸塞總醫院阿爾茨海默病隊列的1,005名參與者的近1,800份血漿樣本,探討了遺傳變異與與阿爾茨海默病相關的蛋白質組變化之間的聯繫。通過結合基於質譜的蛋白質組學和Mendelian隨機化,這項分析發現了健康和患有阿爾茨海默病的個體之間的138個不同丰度的蛋白質組,指出可能與疾病進展相關的可能因果路徑。該方法展示了Seer平台如何促進全面覆蓋,並有效相關遺傳和蛋白質數據,提供對複雜疾病的無偏探索。這項研究推動了對阿爾茨海默病系統因素的理解,可能揭示出新的生物標誌物和治療靶點,而有針對性的方法可能忽略。
人口健康研究:利用新穎的速度和深度實現人群規模的血漿蛋白質組學,推動新的發現
標題:利用納米顆粒富集增強強大的人群規模MS血漿蛋白質組學研究
主講人:李坎特雷爾
日期和時間:10月21日,13:15(海報展示會議P-I-0212)
Seer的Proteograph Xt被應用在一個涉及1,600個血漿樣本的人群研究中,結合納米顆粒富集、基於板的自動化製備和質譜測量,實現了規模上的顯着深度。通過識別超過8,100個蛋白質組,並且處理吞吐量達到每天40個樣本,基於雲的DIA-NN集成加速了數據分析速度,比標準計算框架提高了20倍。通過壓縮血漿蛋白質的動態範圍並增強肽多樣性,這種工作流可避開像手動分離和耗盡這樣的典型瓶頸,以最小化處理時間提供更高覆蓋率。這種能力對於尋找高效生成生物學見解的發現蛋白質組研究人員特別有價值,提供了深度和吞吐量上的顯著增益。
全血微取樣:通過新穎的幹血斑分析擴大蛋白質組學的可及性,用於全面生物標誌物研究
標題:從各種幹血斑收集設備中獲得的全血基於納米顆粒的蛋白質組學分析的進展
主講人:Maik Pruess
日期和時間:10月21日,13:15(海報展示會議P-I-0165)
本研究側重於利用幹血斑(DBS)樣本進行蛋白組學分析,這是一種能夠實現更少侵入性採樣和擁有更廣泛臨床應用的方法。Seer的納米顆粒富集的整合改善了檢測到的蛋白質數量——從大約1,000增加到3,000,相較於傳統的直接處理方法。該方法展示了受試者之間較低的變異性(CV <10%),並展示了Proteograph Xt在涉及最小樣本量的大規模研究中的適用性。通過將DBS與納米顆粒富集相結合,研究人員可以從最少的樣本中進行深入的蛋白質組學分析,這對於早期生物標誌物的發現是關鍵的。與傳統方法相比,這種方法促進了更具包容性和可訪問性的蛋白質研究模式,支持了個體和群體規模上的創新。
異種移植:通過超深度縱向分析捕獲免疫動態,以獲得移植研究的新見解
題目:血漿和血清蛋白質組的超深度縱向分析爲人體器官與豬異種移植的相互作用提供關鍵見解
主講人:Alexey Stukalov
日期與時間:10月22日,11:05(口頭報告OP-43)
在多家知名研究機構的合作伙伴的支持下進行了有關異種移植的開創性研究,賽默飛世爾的Proteograph Xt被用於對接受基因修改豬器官移植的受體的血漿和血清蛋白質組進行超深度分析。Proteograph Xt與愛文思控股Orbitrap Astral MS的先進LC-MS工作流集成,使得在61天時間內全面識別了包括超過100,000個肽在內的人類和豬蛋白質。這爲實時提供了免疫系統反應、補體系統動態和生理適應的詳細視圖。對於專注於人類健康和器官移植的研究人員,該研究凸顯了賽默飛世爾平台支持深度縱向取樣和比較蛋白質組學的能力,有助於識別對於推動異種移植和免疫學研究至關重要的生物標誌物和免疫反應。
外部合作伙伴和客戶利用賽默飛世爾的Proteograph產品套件的亮點
來自世界各地的知名組織在HUPO 2024展示了利用賽默飛世爾Proteograph平台的研究,展示了其在不同蛋白質組學研究中的多功能性和價值。這些合作突顯了賽默飛世爾作爲發現型蛋白質組學和臨床應用之間的關鍵推動者的角色。合作伙伴利用賽默飛世爾的平台進行一系列研究,從藥物發現到臨床前模型,強化了Proteograph產品套件在多樣背景下生成深入和無偏見洞察的有效性。這些海報反映了賽默飛世爾技術如何增強蛋白質組學工作流的敏感性、可擴展性和深度。
外部演示:
- 斯坦福大學
- 主題演講:利用深度數據和遠程監測顛覆醫療保健
- 演講人:邁克爾·斯奈德
- 部分/會話:用於大規模蛋白質組學的新技術
- 日期和時間:10月23日,10:15(會議室1-2)
- Evotec
- 標題:基於納米顆粒的人類生物流體樣本蛋白質組學分析,來自不同患者隊列
- 作者:Carleen Kluger,Giada Marino
- 日期和時間:10月21日,13:15(海報展示P-I-0363)
- 賽默飛世爾(海報1)
- 標題:揭示隱藏的深度:在Orbitrap Astral質譜儀上進行的高通量血漿蛋白質組學工作流程,以增強生物標誌物發現
- 作者:Amirmansoor Hakimi
- 日期和時間:10月21日,13:15(海報展示P-I-0124)
- 賽默飛世爾(海報2)
- 標題:由Orbitrap Exploris 480質譜儀支持的深入和高通量的血漿蛋白組學工作流程,使用基於多納米顆粒工作流程
- 作者:Julian Saba
- 日期 & 時間:10月22日,13:00(海報展示P-II-0661)
- 法國國家衛生醫學研究所 (Inserm)
- 題目:深入分析血漿蛋白質組:我們正在豐富胞外囊泡、血小板還是可溶性蛋白質?
- 作者:Ida Chiara Guerrera
- 日期 & 時間:10月21日,13:15(海報展示P-I-0331)
- 首爾國立大學
- 題目:通過蛋白圖譜分析在患乳腺瘤的犬中發現血漿生物標誌物
- 作者:李鍾雲
- 日期和時間:10月22日,13:00(海報展示P-II-0604)
- 羅傑斯心臟研究中心
- 題目:心力衰竭患者全面血漿蛋白質組學研究:發現和未來方向
- 作者:烏洛什·庫茲馬諾夫
- 日期和時間:10月23日,13:00(海報展示P-III-1048)
- 俄勒岡健康與科學大學(OHSU)
- 題目:利用蛋白譜圖Rise和小鼠模型研究血漿蛋白質組的基本生物決定因素
- 作者:馬克·弗洛裏和馬修·張
- 日期&時間:10月23日,13:00 (海報展區 P-III-0938)
Seer在HUPO 2024的貢獻不僅體現在其研究成果上,還體現在其Proteograph產品套件被領先的學術界和工業團體採用。廣泛的外部研究展示了Seer技術在推動蛋白質組學研究、豐富理解以及推動生物分析前沿方面的適用性和價值。
關於Seer:
Seer是一家生命科學公司,正在開發具有變革性的產品,爲蛋白質組提供了新的通道。Seer的Proteograph產品套件是一個集成解決方案,包括專有的特製納米粒子、消耗品、自動化儀器和軟件,可在幾小時內以規模化的方式進行深入、無偏見的蛋白質組學分析。Seer使Proteograph工作流程高效且易於使用,利用廣泛採用的實驗室儀器,提供了一個分散式解決方案,幾乎可以被任何實驗室採納。Seer的Proteograph產品套件僅用於研究,不適用於診斷程序。欲了解更多信息,請訪問。
如需更多信息,請在HUPO 2024展位#20處諮詢,或通過pr@seer.bio與我們聯繫。
媒體聯繫人:Patrick Schmidt pr@seer.bio
投資者聯繫人: Carrie Mendivil investor@seer.bio